Last week, readers were most interested in a story about what's up Roche's sleeve as it talked about its plans during its investor day.

DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient ...

Danaher Corporation has announced a collaboration with AstraZeneca for diagnostic tools and tests development and ...

The companies will develop and commercialize diagnostic tools to help clinicians determine which patients would benefit from precision medicine treatments.

Danaher Corp on Thursday said it has entered a partnership with AstraZeneca PLC to develop and commercialise tools and tests for precision medicine treatments, including artificial intelligence ...

Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the ...

Danaher and AstraZeneca have formed a partnership to develop diagnostic tools that help clinicians better determine which patients would benefit from precision medicine treatments.

According to the National Institutes of Health, in the United States, it's estimated that over 2 million people are affected by aphasia, a language disorder. In recognition of Aphasia Awareness Month, ...

Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") , which subsidiary is listed on the Main Board of The Stock ...

AstraZeneca today announced the successful completion of the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical ...

Investing.com - Danaher (NYSE: DHR) reported first quarter EPS of $1.88, $0.26 better than the analyst estimate of $1.62. Revenue for the quarter came in at $5.74B versus the consensus estimate of ...

Danaher reported second-quarter adjusted EPS of $1.88, down from $1.92 a year ago, beating the consensus of $1.64. Operating cash flow was $1.3 billion, and non-GAAP free cash flow was $1.1 billion.